Curcumin Antagonizes Glucose Fluctuation-Induced Renal Injury by Inhibiting Aerobic Glycolysis via the miR-489/LDHA Pathway.
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
05
2021
revised:
09
07
2021
accepted:
22
07
2021
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
1
4
2022
Statut:
epublish
Résumé
It has been considered that glucose fluctuation (GF) plays a role in renal injury and is related to diabetic nephropathy (DN) development. But the mechanism is still unclear. Aerobic glycolysis has become a topical issue in DN in recent years. There is an internal connection between GF, aerobic glycolysis, and DN. Curcumin (Cur) is a principal curcuminoid of turmeric and possesses specific protective properties in kidney functions. Cur also participates in the regulation of aerobic glycolysis switch. In this study, we first measured the levels of aerobic glycolysis and evaluated Cur's inhibitory ability in a cell model of HEK-293 under the condition of oscillating high glucose. The results indicated that GF exacerbated inflammation injury, oxidative stress, and apoptosis in HEK-293 cell, while Cur alleviated this cytotoxicity induced by GF. We found that GF increased aerobic glycolysis in HEK-293 cells and Cur presented a dose-dependent weakening effect to this exacerbation. Next, we built a panel of 17 miRNAs and 8 lncRNAs that were previously reported to mediate the Warburg effect. Our RT-qPCR results indicated that GF reduced the miR-489 content in the HEK-293 cell model and Cur could prevent this downregulation. Then, we planned to explore the character of miR-489 in Cur-triggered attenuation of the Warburg effect under GF condition. Our findings presented that Cur prevented GF-triggered aerobic glycolysis by upregulating miR-489 in HEK-293 cells. Next, we choose the miR-489/LDHA axis for further investigation. We confirmed that Cur prevented GF-triggered aerobic glycolysis via the miR-489/LDHA axis in HEK-293 cells. In conclusion, this study presented that Cur prevented GF-triggered renal injury by restraining aerobic glycolysis via the miR-489/LDHA axis in the HEK-293 cell model.
Identifiants
pubmed: 34456629
doi: 10.1155/2021/6104529
pmc: PMC8387199
doi:
Substances chimiques
MIRN489 microRNA, human
0
MicroRNAs
0
Curcumin
IT942ZTH98
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6104529Informations de copyright
Copyright © 2021 Xiaomei Fu et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this article.
Références
Oncogene. 2019 Jul;38(28):5551-5565
pubmed: 30967627
J Biochem. 2020 Apr 1;167(4):365-370
pubmed: 31742336
PLoS One. 2014 Jul 21;9(7):e102941
pubmed: 25047354
Nanotoxicology. 2020 Jun;14(5):638-653
pubmed: 32100595
Pharmazie. 2014 Mar;69(3):203-7
pubmed: 24716410
J Neuropathol Exp Neurol. 2019 Oct 1;78(10):939-948
pubmed: 31504670
Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F561-F575
pubmed: 28228400
Curr Diabetes Rev. 2021 Mar 08;:
pubmed: 33745424
J BUON. 2019 Jul-Aug;24(4):1574-1580
pubmed: 31646811
Iran J Basic Med Sci. 2019 Apr;22(4):376-383
pubmed: 31168341
Eur Rev Med Pharmacol Sci. 2018 Aug;22(16):5082-5090
pubmed: 30178826
Diabetes. 2000 Jul;49(7):1149-55
pubmed: 10909972
Biomed Pharmacother. 2018 Jan;97:1296-1302
pubmed: 29156518
Front Med (Lausanne). 2021 Mar 04;8:656086
pubmed: 33748166
Int J Mol Sci. 2020 Feb 28;21(5):
pubmed: 32121279
Cell Death Dis. 2020 Apr 24;11(4):278
pubmed: 32332718
Mediators Inflamm. 2016;2016:1232103
pubmed: 26966340
Biomed Res Int. 2017;2017:1516985
pubmed: 28194406
Environ Toxicol. 2021 Sep;36(9):1775-1784
pubmed: 34089293
Nat Commun. 2020 Jun 22;11(1):3162
pubmed: 32572027
Nutrients. 2021 Jan 27;13(2):
pubmed: 33514002
Cancer Cell Int. 2020 Aug 6;20:374
pubmed: 32774168
J Cancer. 2020 Aug 27;11(21):6264-6276
pubmed: 33033510
Pharm Biol. 2019 Dec;57(1):778-786
pubmed: 31741405
Cancer Manag Res. 2020 Aug 05;12:6895-6908
pubmed: 32801913
Genes Genomics. 2020 Mar;42(3):291-297
pubmed: 31872383
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
J Cell Biochem. 2010 Apr 15;109(6):1210-21
pubmed: 20135641
Neoplasma. 2017;64(2):244-252
pubmed: 28043152
Nutrients. 2021 Mar 22;13(3):
pubmed: 33809891
Cancer Manag Res. 2020 Jun 25;12:5009-5022
pubmed: 32612388
Atherosclerosis. 2019 Mar;282:121-131
pubmed: 30731284
J Hematol Oncol. 2019 Sep 5;12(1):91
pubmed: 31488218
Cell Cycle. 2020 Oct;19(19):2538-2552
pubmed: 32857667
J Diabetes Res. 2015;2015:796912
pubmed: 26770982
Exp Cell Res. 2020 Mar 15;388(2):111876
pubmed: 31991125
Biochem Biophys Res Commun. 2018 Feb 12;496(3):947-954
pubmed: 29360449
J Res Med Sci. 2019 Aug 28;24:77
pubmed: 31523263
Diabetes Metab Syndr Obes. 2020 Mar 03;13:641-652
pubmed: 32184643
Circulation. 2017 Dec 19;136(25):2451-2467
pubmed: 28971999
Anticancer Drugs. 2015 Jan;26(1):15-24
pubmed: 25229889
Nat Rev Cancer. 2011 Feb;11(2):85-95
pubmed: 21258394
Int J Biochem Cell Biol. 2009 Jan;41(1):40-59
pubmed: 18662800
J Endocrinol Invest. 2014 Jul;37(7):645-51
pubmed: 24859911
Int J Oncol. 2018 Aug;53(2):551-566
pubmed: 29845188
Onco Targets Ther. 2020 Nov 04;13:11289-11299
pubmed: 33177837
Food Chem Toxicol. 2020 Mar;137:111131
pubmed: 31958483
Int J Cancer. 2013 Nov 15;133(10):2504-10
pubmed: 23661584
IUBMB Life. 2016 Jul;68(7):589-96
pubmed: 27278959
Afr Health Sci. 2020 Sep;20(3):1292-1298
pubmed: 33402977
Int J Mol Sci. 2021 Feb 09;22(4):
pubmed: 33572095
Front Genet. 2020 Aug 28;11:962
pubmed: 33005174
Mol Med Rep. 2021 May;23(5):
pubmed: 33760170
Cell Death Dis. 2020 Oct 23;11(10):902
pubmed: 33097691
Biofactors. 2021 Jul;47(4):570-586
pubmed: 33893674
Food Funct. 2020 May 1;11(5):4146-4159
pubmed: 32347864